DelveInsight’s, “Renal Cell Carcinoma Pipeline Insight” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Renal Cell Carcinoma pipeline landscape. It covers the Renal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Renal Cell Carcinoma Treatment Landscape. Click here to read more @ Renal Cell Carcinoma Pipeline Outlook
Key Takeaways from the Renal Cell Carcinoma Pipeline Report
- In January 2025:- Merck Sharp & Dohme LLC:- The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy.
- In January 2025:- Hoffmann-La Roche:- A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment.
- In January 2025:- Exelixis:- This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Approximately 840 eligible subjects with intermediate- or poor-risk advanced or metastatic RCC by IMDC criteria will be randomized in a 1:1 ratio at approximately 180 sites.
- DelveInsight’s Renal Cell Carcinoma Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Renal Cell Carcinoma treatment.
- The leading Renal Cell Carcinoma Companies such as AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.
- Promising Renal Cell Carcinoma Therapies such as PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.
Discover groundbreaking developments in Renal Cell Carcinoma therapies! Gain in-depth knowledge of key Renal Cell Carcinoma clinical trials, emerging drugs, and market opportunities @ Renal Cell Carcinoma Clinical Trials Assessment
Renal Cell Carcinoma Emerging Drugs Profile
- CM082: Betta Pharmaceuticals
CM082 series have the similar skeletal structures to Icotinib Hydrochloride, as the multi-target RTK (receptor tyrosine kinase) inhibitor, mainly targeting at VEGFR and PDGFR. The drug is being evaluated in phase III stage of development for the treatment of Renal Cell Carcinoma.
- TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
TQB 2450 (formerly APL 502 and CBT 502) is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1. Phase III clinical trials are being evaluated by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. for TQB 2450 for the treatment of renal cell carcinoma.
- IPI-549: Infinity Pharmaceuticals
IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The drug is being studied in phase II stage of development for the treatment of renal cell carcinoma.
- CMN-001: ColImmune
Dendritic cells have been used by colimmune for the treatment of renal failure. CMN001 is a dendritic cell vaccine for renal cell carcinoma. The drug is being evaluated in phase II stage of development for the treatment of renal cell carcinoma.
Stay informed about the Renal Cell Carcinoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Renal Cell Carcinoma Unmet Needs
Renal Cell Carcinoma Companies
AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.
Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Oral
- Subcutaneous
- Intravenous
- Intramuscular
- Molecule Type
Renal Cell Carcinoma Products have been categorized under various Molecule types such as
- Bispecific Antibody
- Peptides
- Small molecule
- Gene therapy
- Product Type
Transform your understanding of the Renal Cell Carcinoma Pipeline! See the latest progress in drug development and clinical research @ Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspectives
Scope of the Renal Cell Carcinoma Pipeline Report
- Coverage- Global
- Renal Cell Carcinoma Companies- AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.
- Renal Cell Carcinoma Therapies- PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.
- Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Oncology Research–Access the Full Renal Cell Carcinoma Pipeline Analysis Today! @ Renal Cell Carcinoma Drugs and Companies
Table of Content
- Introduction
- Renal Cell Carcinoma Executive Summary
- Renal Cell Carcinoma: Overview
- Renal Cell Carcinoma Pipeline Therapeutics
- Renal Cell Carcinoma Therapeutic Assessment
- Renal Cell Carcinoma – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Renal Cell Carcinoma Collaboration Deals
- Late Stage Products (Phase III)
- TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- IPI-549: Infinity Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- AVB-S6-500: Aravive Inc.
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Drug Name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Renal Cell Carcinoma Key Companies
- Renal Cell Carcinoma Key Products
- Renal Cell Carcinoma – Unmet Needs
- Renal Cell Carcinoma – Market Drivers and Barriers
- Renal Cell Carcinoma – Future Perspectives and Conclusion
- Renal Cell Carcinoma Analyst Views
- Renal Cell Carcinoma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market